Tae‐Yong Kim

3.6k total citations
125 papers, 2.4k citations indexed

About

Tae‐Yong Kim is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Tae‐Yong Kim has authored 125 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Oncology, 45 papers in Pulmonary and Respiratory Medicine and 25 papers in Surgery. Recurrent topics in Tae‐Yong Kim's work include Gastric Cancer Management and Outcomes (18 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (18 papers) and HER2/EGFR in Cancer Research (17 papers). Tae‐Yong Kim is often cited by papers focused on Gastric Cancer Management and Outcomes (18 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (18 papers) and HER2/EGFR in Cancer Research (17 papers). Tae‐Yong Kim collaborates with scholars based in South Korea, United States and Ethiopia. Tae‐Yong Kim's co-authors include Seock‐Ah Im, Do‐Youn Oh, Kyung-Hun Lee, Sae‐Won Han, Yung‐Jue Bang, Tae‐You Kim, Jongwon Kim, Ahrum Min, Tae‐You Kim and Younak Choi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Tae‐Yong Kim

121 papers receiving 2.4k citations

Peers

Countries citing papers authored by Tae‐Yong Kim

Since Specialization

Citations

This map shows the geographic impact of Tae‐Yong Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tae‐Yong Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tae‐Yong Kim more than expected).

Fields of papers citing papers by Tae‐Yong Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tae‐Yong Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tae‐Yong Kim. The network helps show where Tae‐Yong Kim may publish in the future.

Co-authorship network of co-authors of Tae‐Yong Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Tae‐Yong Kim. A scholar is included among the top collaborators of Tae‐Yong Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tae‐Yong Kim. Tae‐Yong Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Multicenter single-arm phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab 2025 ·Journal of Hepatology ·Hyung‐Don Kim, Sun Jin Sym, Hong Jae Chon, (unknown), Jung Hun Kang, Baek‐Yeol Ryoo, Choong‐kun Lee, Joo-Hyun Hong, Hyewon Ryu, (unknown), Hyeyeong Kim, Hyunho Kim, Jin Won Kim, Tae‐Yong Kim, Changhoon Yoo	3
2	Fadraciclib, a CDK2/CDK9 inhibitor, shows efficacy in biliary tract cancer and synergistic potential with olaparib and JQ1 based on MCL1 expression 2025 ·Cell Communication and Signaling ·Jae‐Min Kim, (unknown), (unknown), Ju‐Hee Bang, (unknown), (unknown), (unknown), Su In Lee, (unknown), Tae‐Yong Kim, Do‐Youn Oh	0
3	Blood Pb levels are associated with prostate cancer prevalence among general adult males: Linking National Cancer Registry (2002–2017) and KNHANES (2008–2017) databases of Korea 2024 ·International Journal of Hygiene and Environmental Health ·(unknown), (unknown), Ejin Kim, Inae Lee, Young Joo Park, Tae‐Yong Kim, Min Joo Kim, Shinje Moon, Sangah Shin, Ho Kim, Kyungho Choi	6
4	ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2–Positive Gastric or Gastroesophageal Junction Adenocarcinoma 2023 ·Clinical Cancer Research ·Samuel J. Klempner, Keun‐Wook Lee, Kohei Shitara, Jean‐Philippe Metges, Sara Lonardi, David H. Ilson, Nicola Fazio, Tae‐Yong Kim, Li‐Yuan Bai, Diarmuid Moran, (unknown), Ahsan M. Arozullah, (unknown), Jeffrey J. Raizer, Yung‐Jue Bang, Manish A. Shah	44
5	Recent Progress in Immunotherapy for Gastric Cancer 2023 ·Journal of the Korean Gastric Cancer Association ·(unknown), Tae‐Yong Kim, Do‐Youn Oh	23
6	Analysis of the role of tumor microenvironment on clinical outcomes of chemotherapy in patients with advanced gastric cancer using high plex digital spatial profiling. 2023 ·Journal of Clinical Oncology ·Tae‐Yong Kim, Hye Seung Lee, (unknown), Yujun Park, Do‐Youn Oh, (unknown), Soo Kyung Nam, Yoonjin Kwak	1
7	Multibranched Au–Ag–Pt Nanoparticle as a Nanozyme for the Colorimetric Assay of Hydrogen Peroxide and Glucose 2022 ·ACS Omega ·Gyubok Lee, Changheon Kim, (unknown), (unknown), Tae‐Yong Kim, (unknown), Kangwon Lee	25
8	Psychiatric symptoms mediate the effect of resilience on health‐related quality of life in patients with breast cancer: Longitudinal examination 2021 ·Psycho-Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Won‐Hyoung Kim, Dooyoung Jung, Tae‐Yong Kim, Seock‐Ah Im, Kyung‐Hun Lee, Eun‐Jung Shim, Bong‐Jin Hahm	9
9	Prognostic Role of Androgen Receptor Expression in Surgically Resected Early Breast Cancer Patients 2020 ·Journal of Breast Cancer ·Yaewon Yang, Ahrum Min, Kyung-Hun Lee, Han Suk Ryu, Tae‐Yong Kim, (unknown), Koung Jin Suh, Dae‐Won Lee, Han‐Byoel Lee, Hyeong‐Gon Moon, Wonshik Han, In Ae Park, Dong‐Young Noh, Seock‐Ah Im	9
10	Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib 2020 ·Clinical Cancer Research ·Dae-Won Lee, Eun Ju Cho, (unknown), Su Jong Yu, Yoon Jun Kim, Jung‐Hwan Yoon, Tae‐Yong Kim, Sae‐Won Han, Do‐Youn Oh, Seock‐Ah Im, Tae‐You Kim, Young-Eun Lee, Haeryoung Kim, Kyung-Hun Lee	33
11	Quality of life outcomes including neuropathy‐associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first‐line chemotherapy for HER2‐negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13‐11) 2019 ·Cancer Communications ·Ji‐Yeon Kim, Seri Park, Seock‐Ah Im, Sung‐Bae Kim, Joohyuk Sohn, Keun Seok Lee, Yee Soo Chae, Ki Hyeong Lee, Jee Hyun Kim, Young‐Hyuck Im, Tae‐Yong Kim, Kyung‐Hun Lee, Jin‐Hee Ahn, Gun Min Kim, In Hae Park, Soo Jung Lee, Hye Sook Han, Se Hyun Kim, Kyung Hae Jung, Yeon Hee Park, (unknown)	3
12	AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells 2017 ·Molecular Cancer Therapeutics ·Ahrum Min, Seock‐Ah Im, Hyemin Jang, Seongyeong Kim, Miso Lee, (unknown), Yaewon Yang, Hee Jun Kim, Kyung-Hun Lee, Jin Won Kim, Tae‐Yong Kim, Do‐Youn Oh, (unknown), Alan Lau, Mark J. O’Connor, Yung‐Jue Bang	105
13	Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor–Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors 2017 ·Cancer Research and Treatment ·Koung Jin Suh, Se Hyun Kim, Kyung-Hun Lee, Tae‐Yong Kim, Yu Jung Kim, Sae‐Won Han, Eunyoung Kang, Eun‐Kyu Kim, Kidong Kim, Jae Hong No, Wonshik Han, Dong‐Young Noh, Maria Lee, Hee Seung Kim, Seock‐Ah Im, Jee Hyun Kim	12
14	Src as a Therapeutic Target in Biliary Tract Cancer 2016 ·Molecular Cancer Therapeutics ·Ah-Rong Nam, Ji‐Won Kim, Ji Eun Park, Ju-Hee Bang, Mei Hua Jin, Kyung-Hun Lee, Tae‐Yong Kim, Sae‐Won Han, Seock‐Ah Im, Tae‐You Kim, Do‐Youn Oh, Yung‐Jue Bang	9
15	Longitudinal Association of Poor Sleep Quality With Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer 2016 ·Psychosomatic Medicine ·Dooyoung Jung, (unknown), Won‐Hyoung Kim, Joo-Young Lee, Tae‐Yong Kim, Seock‐Ah Im, Kyung-Hun Lee, David Spiegel, Bong‐Jin Hahm	22
16	Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea 2016 ·Cancer Research and Treatment ·Seung‐Hoon Beom, Jisu Oh, Tae‐Yong Kim, Kyung-Hun Lee, Yaewon Yang, Koung Jin Suh, Hyeong‐Gon Moon, Sae‐Won Han, Do‐Youn Oh, Wonshik Han, (unknown), Dong‐Young Noh, Seock‐Ah Im	2
17	Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer 2015 ·Clinical Cancer Research ·Chan-Young Ock, Keun‐Wook Lee, Jin Won Kim, Jin-Soo Kim, Tae‐Yong Kim, Kyung-Hun Lee, Sae‐Won Han, Seock‐Ah Im, Tae-You Kim, Woo Ho Kim, Yung‐Jue Bang, Do‐Youn Oh	52
18	Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer 2015 ·Journal of Cancer Research and Clinical Oncology ·Ji‐Won Kim, (unknown), Ahrum Min, Kyung-Hun Lee, (unknown), Jee Hyun Kim, Jin-Soo Kim, Tae‐Yong Kim, Seock‐Ah Im, In Ae Park	36
19	Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma 2015 ·BMC Cancer ·Kyung-Hun Lee, Kyoung Bun Lee, Tae‐Yong Kim, Sae‐Won Han, Do‐Youn Oh, Seock‐Ah Im, Tae‐You Kim, Nam‐Joon Yi, Kwang‐Woong Lee, Kyung‐Suk Suh, Ja–June Jang, Yung‐Jue Bang	20
20	HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer 2013 ·Cancer Chemotherapy and Pharmacology ·Ji‐Won Kim, Jee Hyun Kim, Seock‐Ah Im, Yu Jung Kim, (unknown), Jin‐Soo Kim, Kyung-Hun Lee, Tae‐Yong Kim, Sae‐Won Han, Yoon Kyung Jeon, Do‐Youn Oh, Tae‐You Kim, In Ae Park	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact